Endo lists debt impacted by event of default via bankruptcy filing

Chicago, Aug. 19 – Endo International plc reported in an 8-K filing with the Securities and Exchange Commission that the company’s filing for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Southern District of New York constituted an event of default and accelerated the company’s obligations.

The company listed the obligations impacted with more details added from a court filing:

• A credit agreement from April 27, 2017 with JPMorgan Chase Bank, NA as administrative agent that was most recently amended and restated on March 25, 2021 that listed $5,869,913.457.85 outstanding;

• The 5 3/8% senior notes due 2023 from June 30, 2014;

• The 6% senior notes due 2025 issued on Jan. 27, 2015;

• The $300 million of 5 7/8% senior secured notes due 2024 issued on April 27, 2017;

• The $2,015,479,000 of 7˝% senior secured notes due 2027 issued on March 28, 2019;

• The $940.59 million 9˝% senior secured second-lien notes due 2027 issued on June 16, 2020;

• The 6% senior notes due 2028 issued on June 16, 2020; and

• The $1,295,000,000 6 1/8% senior secured notes due 2029 issued on March 25, 2021.

As a result of the filing, the principal and interest are supposedly due immediately.

The company believes that enforcement of the obligations is stayed by the bankruptcy filing.

Endo is a Dublin, Ireland-based specialty pharmaceutical company. The Chapter 11 case number is 22-22549.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.